25 citations
,
July 1994 in “Archives of Dermatology” A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.
April 2026 in “Clinical Dermatology Review” Keratosis pilaris significantly affects quality of life and shows specific skin changes.
10 citations
,
May 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
26 citations
,
June 2003 in “PubMed” Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.
3 citations
,
July 2025 in “International Immunopharmacology”
April 2023 in “Journal of Investigative Dermatology” Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
August 1994 in “Journal of dermatological science” Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.
54 citations
,
December 2014 in “Wound Repair and Regeneration” PRP injections may improve hair thickness and density in female hair loss patients.
June 2022 in “International Journal of Research in Dermatology” Injectable platelet-rich fibrin is a safe and effective treatment for hair loss.
26 citations
,
June 2005 in “Journal of The American Academy of Dermatology” Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.
2 citations
,
November 1998 in “Journal of The European Academy of Dermatology and Venereology” A patient with a severe type of hair loss experienced partial hair regrowth after treatment with a specific light therapy and a medication called interferon α2a.
The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
1 citations
,
May 2025 in “Natural Products and Bioprospecting” PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.
2 citations
,
January 2007 in “Acta Dermato Venereologica” A patient developed a blister at the injection site after hepatitis C treatment.
39 citations
,
January 2006 in “Journal of Cosmetic and Laser Therapy” Pneumatic Skin Flattening (PSF) significantly reduces pain during laser and IPL hair removal.
December 2025 in “International Journal of Pharmacology” iPSC-derived artificial platelets show promise for consistent and effective regenerative therapies.
1 citations
,
October 2024 in “Indian Dermatology Online Journal” January 2017 in “Seoul National University Open Repository (Seoul National University)” AIMP1 can boost hair growth by increasing stem cell activity.
April 2026 in “Journal of Dermatological Treatment” CGF and i-PRF are more effective and safer than PRP for treating female pattern hair loss.
19 citations
,
May 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” The type 3 IP3 receptor is important for controlling hair loss and growth.
Microneedling improves the appearance and feel of post-burn scars.
10 citations
,
June 2019 in “Dermatologic therapy” DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.
Targeting the PGI2 pathway may help heal diabetic foot ulcers.
280 citations
,
January 2004 in “The EMBO Journal” AGC2-1 protein is essential for root hair growth in Arabidopsis.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
13 citations
,
March 2013 in “International Journal of Cosmetic Science” AcSDKP may help prevent skin and hair aging and promote their growth.
2 citations
,
December 2011 in “[Thesis]. Manchester, UK: The University of Manchester; 2011.” Immune system failure in hair follicles causes lichen planopilaris, leading to hair loss.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.